Connected data gives you a clearer picture
At Evaluate we collect, calibrate and connect the pharmaceutical world's data.
Our commercial intelligence and analysis are used by the Financial Times, the Wall Street Journal, Forbes, Nature, and Reuters, among others.
Take a look at the latest Evaluate and Evaluate Vantage coverage. To learn more about how we work with healthcare and business reporters worldwide, or if you are looking for specific data and expert insights to support a current story, please contact us at [email protected].
Having supplanted Novartis as the biggest pharma company by prescription sales in 2019, Roche managed to hang onto the title in 2020.
There were more than 900 pharmaceutical deals valued at about $800 billion between 2016 and 2020, according to a market-research firm, EvaluatePharma.
Global sales of generics are expected to reach $100 billion by 2024, according to the research firm EvaluatePharma, up from $75 billion in 2018.
Evaluate Pharma forecasts Aimovig to maintain its lead up to 2024, with estimated sales of $2.05bn that year. It also predicts Emgality could hit $1.2bn by 2024.
EvaluatePharma has predicted that risdiplam could become an $800m-plus drug by 2024, and other analysts have said it could make upwards of $2.5bn at its peak.
For comparison, while Tecfidera is a billion-dollar product, EvaluatePharma has forecast sales of Vumerity to reach a modest $111m in 2024.
Evaluate Pharma projects that Palforzia could be a blockbuster drug that brings in more than $1 billion in annual sales by 2024.
Evaluate Pharma forecasts Aimovig to maintain its lead up to 2024, with estimated sales of $2.05bn that year. It also predicts Emgality could hit $1.2bn by 2024, with…
And according to Evaluate Pharma, it's a blockbuster approval. Palforzia could hit an estimated $1.28 billion in sales by 2024, the firm said, as an immunotherapy that…
EvaluatePharma has said selpercatinib could become a $500 million-plus product by 2024.
Conatus’ fate “serves to underline the risks of NASH,” Vantage wrote in June after its pan-capsase inhibitor, emricasan, failed its third NASH study.
EvaluatePharma has previously predicted that sales of ALKS 381 could reach $381m in 2024 if approved, which would be a sizeable addition to its current revenues, expected…
Projections from EvaluatePharma are quoted by the study, showing that the sector will experience compound annual growth of 6.9% for global prescription drug sales.